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Objective.Todetermine the contributions of bodymass, adiposity, andmuscularity to physical function andmuscle strength in adult
patients with Bethlem myopathy (BM) and Ullrich congenital muscular dystrophy (UCMD). Materials and Methods. Evaluation
involved one UCMD and 7 BM patients. Body composition was determined by body mass index (BMI) and dual-energy-X-ray-
absorptiometry (DXA), muscle strength by dynamometry, physical function by the distance walked in 6 minutes (6MWD), forced
vital capacity (FVC) by a spirometer. Results. Six participants were of normal weight and 2 overweight based on BMI; all were
sarcopenic based on appendicular fat free mass index (AFFMI); and 7 were sarcopenic obese based on AFFMI and % fat mass.
Average muscle strength was reduced below 50% of normal. The 6MWD was in BM patients 30% less than normal. FVC was
reduced in 4 of the BM patients. Muscle strength had a good correlation with the physical function variables. Correlation between
muscle strength and BMI was poor; it was very high with AFFMI. AFFMI was the best single explicator of muscle strength and
physical function. Conclusion.Muscle mass determined by DXA explains most of the variability of the measures of muscle strength
and physical function in patients with BM and UCMD.
1. Introduction
Mutations in any of the three genes (COL6A1, COL6A2, and
COL6A3) coding for collagenVI, amajor extracellularmatrix
protein of the endomysium of skeletal muscles, cause the col-
lagen VI-relatedmyopathies [1] including Bethlemmyopathy
(BM), Ullrich congenital muscular dystrophy (UCMD), and
the two rarer variants limb girdle andmyosclerosis myopathy
[2, 3]. Bethlem myopathy is a congenital or early-onset mus-
cular dystrophy characterized by axial and proximal muscle
weakness [4, 5], and the hallmark of the disease is the pres-
ence of contractures of the interphalangeal joints of the last
four fingers [6]. Bethlem myopathy is usually mild, some-
times slowly progressive, with some affected individuals over
50 years of age needing aids for outdoors mobility [7]. Respi-
ratory failure is part of the clinical spectrum and can occur in
patients with preserved ambulatory function [8]. UCMD is a
severe congenital muscular dystrophy characterized by early
onset, generalized and rapidly progressive muscle wasting
and weakness, proximal joint contractures, and distal joint
hyperflexibility. Independent ambulation is not achieved in
the severe cases or is lost during childhood/adolescence in
most cases [9–11]. Respiratory failure is early and progressive
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and may require artificial ventilatory support in the first or
second decade of life [7].
In the EU, a rare disease is one which affects fewer than 5
people per 10,000 [12]. COL6 myopathies, although probably
under diagnosed [13], are very rare disorders with the preva-
lence estimated as 0.77 per 100,000 for BM and 0.13 per
100,000 for UCMD [14].
The turning point in basic research on collagen VI myo-
pathies was the discovery that mitochondrial dysfunction
mediated by inappropriate opening of the permeability tran-
sition pore plays a key role [15–18]; defective autophagy with
impaired removal of defective mitochondria amplifies the
defect [19]; and reactivation of autophagy with a low-protein
diet or treatmentwith cyclosporineA, themitochondrial PTP
inhibitor, cured Co6a1−/− mice [15], hinting at a common
target among all beneficial treatments—namely, autophagy
[19, 20].
From a scientific and clinically relevant standpoint, the
identification, measurement, and treatment monitoring of
muscular dystrophy using a single easily administered cost
effective test or measure is not currently possible [13]. There-
fore, in clinical trials the methodological approach should be
as comprehensive and multidimensional as possible, possibly
evaluating the same aspect of skeletal muscle with different
tools/instruments, to obtain confirmatory evaluations to
findings [21]. Clinical trials have already involved paediatric
patients with UCMD [17, 18] and planned for adult patients
with collagen type VI myopathies aiming at correcting
defective autophagy [22, 23]. Muscular dystrophy is charac-
terized by an interconnected decline in muscle mass, muscle
strength, andmuscle function.Therefore, it would bemanda-
tory to include a test of all these aspects as the best assessment
in clinical trials.The purpose of this study is to determine the
relative contributions of body mass, adiposity, and muscu-
larity to measured physical function and muscle strength in
adult patients with COL6 related myopathies.
2. Materials and Methods
We reviewed the records of our 75 patients with a clinical/
laboratory phenotype compatible with the diagnosis of BM/
UCMD [7]. Forty-four had a definite molecular diagnosis
with recognition of a pathogenetic mutation/s in one of the
three COL6 genes [3, 24–30]. Of the 27 patients, aged 18
years or more, 22 had a diagnosis of BM, 3 of myosclerosis
myopathy, and 2 of UCMD. Fourteen of these, who have been
followed in the previous 12months, were contacted. 8 patients
(5 female, 3 male, mean age 31 ± 9) with collagen type VI
related myopathies accepted to be included in this study. The
7 BM patients were ambulatory, while the one with UCMD
was never able towalk andwas onnocturnal noninvasive ven-
tilation.The study protocol was approved by the institutional
ethical committee. All subjects were fully informed and gave
their written informed consent.
Body composition was obtained by DXA (Hologic 4500
W; software version 11.2; Hologic, Inc., Waltham, MA).
According to the tree-compartment model of body composi-
tion the Hologic software provided regional and whole body
estimation of lean mass (LM), fat mass (FM), and bone min-
eral content (BMC). BMC and LM were added to obtain fat
free mass (FFM). Appendicular fat free mass (AFFM) rep-
resents the sum of both arms and legs [31]. Body mass, FM,
FFM, and AFFM were normalized to height 2 as control for
skeletal size [32]. Women with appendicular fat free mass
index (AFFMI) <5.45 and men <7.26 were classified as sar-
copenic [31, 32]. BMI, an index of obesity, was derived from
body mass measured by DXA to the nearest gram and height
measured to the nearest 0.1 cm. We used BMI to categorized
participants as obese (BMI≥ 30), overweight (25≤BMI< 30),
or normal weight (BMI < 25) [33]. In addition subjects were
classified as obese if their percentage body fat derived from
DXA was above the 90th percentile of the Italian population
[34]. For men, this cutpoint was 30% body fat; for women,
it was 41% body fat [34]. Maximal isometric strength was
assessed using a hand-held dynamometer (Type CT 3001,
Citec, C.I.T. Technics BV, Groningen, The Netherlands) [35].
Four muscle groups were examined bilaterally: hand grip,
elbow flexors, knee extensors, and knee flexors [36–38]. Each
individualmuscle groupwas tested for at least 3 seconds using
a “make” test [37]. The maximum force from three attempts
was used in analysis. A composite score (megascore) was cal-
culated by summing the maximal force of the 8 tests for each
patient [38, 39]. Forced vital capacity (FVC) was determined
with an electronic spirometer, and per cent-predicted values
were calculated based on normal published values. A value
between 50% and 70% was considered moderately reduced; a
value less than 50% was considered severely reduced [8]. The
6minute walk test (6MWT)was performed in a corridor, and
standardized verbal instructions were given every minute.
Timed tests include the time towalk 10mand to climb 4 steps.
3. Statistical Analysis
The very limited sample size suggested using simple linear
regression models to determine the separate relative con-
tributions of the various indices. Linear correlation coeffi-
cients have, therefore, been computed for various couples of
variables with the aim of choosing the variables for simple
linear models without intercept. High values of the linear
correlation coefficients help in the choice of identifying the
variables with potentially similar meaning for choosing both
the dependent and the explanatory variables. The separate
relative contributions of body mass and muscularity (seen
as explanatory variables) to muscle strength, 6MWD, and
pulmonary function (i.e., dependent variables) were evalu-







, without intercept. Each 𝛽 coefficient was estimated via
ordinary least squares. The values of this coefficient denote
the increment/decrement of the dependent variable for a
unit increment of each explanatory variable. To evaluate the
strength of each simple linear relationship, we used the good-
ness of fit measure 𝑅2. Measurable variables are presented as
mean (𝑥) ± standard deviation (SD) and categorical data as
number and percentage.
4. Results
4.1. Body Composition. 6 participants were of normal weight
and 2 were overweight based on BMI, all were sarcopenic
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Table 1: Body mass, adiposity, and muscularity. Summaries of
individual data grouped according to sex.
Variable Women (𝑛 = 5) Men (𝑛 = 3)
Total mass (kg) 66.7 ± 12.1(range: 45–74)
66.3 ± 11.1
(range: 55–77)
BMI (kg/m2) 22.9 ± 4.2(range: 18–29)
22.3 ± 3.6
(range: 18–26)
% FM 51.6 ± 6.6(range: 41–59)
34.6 ± 14.2
(range: 18–44)
FMI (kg/m2) 12.0 ± 3.6(range: 7–17)
8.0 ± 4.0
(range: 3–11)
FFMI (kg/m2) 10.9 ± 0.8(range: 10–12)
14.3 ± 1.3
(range: 13–15)
AFFMI (kg/m2) 4.2 ± 0.8(range: 3–5)
5.8 ± 0.6
(range: 5–6)
BMI: body mass index, FM: fat mass, FMI: fat mass index, FFMI: fat free
mass index, AFFMI: appendicular fat free mass index.
based on AFFMI, and 7 were sarcopenic obese based on
AFFMI and% fatmass (Table 1). FFMIwas well below the 5th
percentile for all the patients as compared to the normal age
related population and also to the 70–80-year-olds [34]. The
sex differences in body composition were as expected, with
women having similar BMI but significantly greater adiposity
and less muscularity than men.
4.2. Muscle Strength and Physical Function. Muscle strength
(Table 2) was reduced in allmuscle groups comparedwith the
normative values [35, 40]. In particular, knee extension and
elbow flexion were the weakest compared with healthy sub-
jects in which knee extension exceeds in all 250N, and elbow
flexion exceed 150N in women and 250N in men [35, 40].
The mean 6MWD was in the 7 walkers 415 ± 71m (418 ±
38m in women and 411 ± 105 in men) as compared to 593 ±
57 and 638 ± 44, respectively, in women and men healthy
Italian subjects in the same age range [41]. In BM patients
%FVC was moderately (<70%) reduced in three and severely
reduced (<50%) in one. The UCMD patient with a FVC of
14% was on mechanical ventilation.
4.3. Correlation between Body Composition, Muscle Strength
and Physical Function. All the muscle strength measures
had a good correlation with the physical function variables
(Table 3).Themegascore, in particular, showed very good lin-
ear correlation with all the physical function variables (0.72–
0.92), stressing its value of muscular strength synthesis. The
single measures of physical strength exhibited more variable
values (0.38–0.96). Hand grip, in addition to being an impor-
tant component of megascore and the most easy to perform
and repeatable test, had a very strong linear correlation with
FVC and %FVC (𝑟 = 0.96 and 𝑟 = 0.89, resp.).
The linear correlation coefficients between couples of pos-
sible explicative variables of body mass and muscularity were
different. Highest values, oscillating between 0.95 and 0.98,
occurred between all measures (FFM, FFMI, AFFM, and
AFFMI) derived byDXAbut were very low between BMI and
all these DXA measures of muscularity (0.08–0.17).
Table 2: Muscle strength and measured physical function. Sum-
maries of individual data grouped according to sex.
Variable Women (𝑛 = 5) Men (𝑛 = 3)
Hand grip (N) 47.3 ± 18.8(range: 12–73)
99.0 ± 22.8
(range: 67–119)
Elbow flexion (N) 38.8 ± 13.7(range: 10–52)
99.3 ± 25.0
(range: 59–133)
Knee extension (N) 76.2 ± 38.2(range: 24–136)
126.3 ± 77.6
(range: 50–225)
Knee flexion (N) 76.7 ± 31.5(range: 18–107)
123.0 ± 55.4
(range: 54–185)
Megascore (N) 478 ± 199(range: 160–680)
895 ± 286
(range: 651–1210)
10m (1/𝑇) 0.11 ± 0.07(range: 0–0.17)
0.13 ± 0.04
(range: 0.09–0.18)
4 steps (1/𝑇) 0.14 ± 0.09(range: 0–0.22)
0.24 ± 0.09
(range: 0.17–0.33)
6MWD (m) 335 ± 190.2(range: 0–458)
411 ± 104.5
(range: 320–525)
FVC (mL) 1788 ± 863(range: 460–2670)
3687 ± 832
(range: 2760–4370)
% FVC 49 ± 23.0(range: 14–72)
73.0 ± 17.3
(range: 53–84)
N: Newton, 𝑇: time, 6MWD: 6 minute walking distance, FVC: forced vital
capacity.
Table 3: Linear correlation coefficients between muscle strength






Megascore (N) 0.74 0.72 0.92 0.89 0.78
Hand grip (N) 0.62 0.58 0.77 0.96 0.89
Elbow flexion (N) 0.45 0.38 0.62 0.94 0.81
Knee extension (N) 0.66 0.65 0.82 0.62 0.53
Knee flexion (N) 0.77 0.80 0.90 0.67 0.59
6MWD: 6 minute walking distance, 𝑇: time, FVC: forced vital capacity, N:
Newton.
The indices of adiposity, BMI and FMI, had a negative
correlation with all themuscle strength and physical function
variables; BMI correlation coefficients, in particular, were
very low and close to independence (Table 4). On the con-
trary, the indices of muscularity FFMI and AFFMI showed
strong positive values when associated with all the dependent
variables (Table 4). The highest values of linear correlation
occurred between measures of muscle strength and partic-
ularly the megascore and FFMI (𝑟 = 0.87), and AFFMI (𝑟 =
0.93), indicating in this case a strong linear association and
not a mere replication of the same information.
Body compositions measures (Table 5), expressed alter-
natively via BMI and AFFMI, behaved very similarly when
proposed as linear explicators of indicators ofmuscle strength
(megascore and hand grip) and physical function (6MWD
and%FVC). BMI was a good linear explicator, with 𝑅2 values
varying from 0.77 to 0.85; however, the best single explicator
was AFFMI, with 𝑅2 values varying from 0.90 to 0.93.
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Table 4: Linear correlation coefficients between potential depen-
dent (lines) and explanatory (columns) variables.
BMI FMI FFMI AFFMI
Megascore (N) −0.06 −0.49 0.87 0.93
Hand grip (N) −0.26 −0.59 0.71 0.76
Elbow flexion (N) −0.10 −0.46 0.74 0.76
Knee extension (N) 0.07 −0.30 0.75 0.82
Knee flexion (N) −0.03 −0.41 0.78 0.83
6MWD (m) −0.13 −0.32 0.41 0.52
10m (1/𝑇) −0.26 −0.44 0.40 0.49
4 steps (1/𝑇) −0.12 −0.45 0.68 0.78
FVC (mL) −0.04 −0.42 0.78 0.86
% FVC −0.02 −0.30 0.57 0.68
BMI: body mass index, FMI: fat mass index, FFMI: fat free mass index,
AFFMI: appendicular fat free mass index, N: Newton, 6MWD: 6 minute
walking distance, 𝑇: time, FVC: forced vital capacity.






) of separate relative contribu-







Megascore (N) BMI 27.22 0.81
AFFMI 141.05 0.94
Hand grip (N) BMI 2.82 0.77
AFFMI 14.64 0.91
6MWD (m) BMI 15.52 0.82
AFFMI 77.58 0.90
% FVC BMI 2.50 0.85
AFFMI 12.48 0.93
𝑅
2: coefficient of determination, 6MWD: 6 minute walking distance, N:
Newton, FVC: forced vital capacity.
5. Discussion
Themain objective of this study was to measure and correlate
body composition, muscle strength, and physical function in
a cohort of patients with collagen VI related myopathies.
Body composition was evaluated with BMI and DXA.
Body fat was greatly underestimated by BMI that classified
only 2 patients as overweight while all but one resulted obese
according to their percentage of body fat derived by DXA. In
addition, DXA showed that all patients had a great reduction
inmuscularity both in the total body as indicated by the FFMI
and particularly in the limbs with the AFFMI so that all could
be classified sarcopenic [31, 32]. It should be stressed that BMI
determinations do not measure body fat directly nor distin-
guish between fat and lean (nonfat) body mass. In fact, in
patients there was no evident linear relationship (correlation
coefficients ranging from 0.08 to 0.17) between BMI and the
measures of muscularity derived by DXA. BMI correlates to
directmeasures of body fat, such as underwater weighing and
DXA for most normal people [42, 43]. However, DXA, pro-
viding whole body and regional estimation of skeletal muscle
mass in vivo [44], is particularly relevant for the evaluation
of body composition in neuromuscular patients who are
undermuscled to body size [45–48].
Muscle strength, measured with a dynamometer, was
diffusely reducedwith average values less than 50% of normal
in the tests of knee extension, hand grip, and elbow flexion.
All the measures of physical functions were reduced in
these patients. The distance walked in 6 minutes was in the
7 BM patients 30% less than in normal age-matched subjects
[41]. %FVCwas reduced in 4 of the 7 BM,moderately (<70%)
in 3, and severely in one (<50%). In a cohort of 43 BM
patients, FVC was found moderately reduced in 7 (16%) and
severely reduced in 2 [8].Our figures further stress the impor-
tance to regularly evaluate the respiratory function not only
in UCMD but also in BM patients [8, 10, 49].
Muscle strength was positively correlated with the mea-
sures of physical function. The megascore showed strong
correlation with all the physical functions, respiratory func-
tions (0.78–0.89), time to climb 4 steps (0.92), time to
walk 10m (0.72), and 6MWD (0.74). A good relationship
betweenmotor ability andmuscle strength has been found in
patients with neuromuscular disorders confirming that loss
of function is due to loss of muscle strength [37, 50, 51]. Most
myopathies, including collagen VI-related myopathies, are
slowly progressive disorders characterized by muscle wasting
and weakness that compromise motor and respiratory func-
tions. If a cure is available, it should have a positive effect on
muscle strength [13].
The various indices of body composition showed very
different correlation with the measures of muscle strength
and of physical function. It should be noted that muscle mass
is the primary determinant of muscle strength in normal
subjects [52, 53]. This statement was also true in our patients,
in whom the indices of muscularity (FFMI and AFFMI) were
strongly correlated with muscle strength. AFFMI showed the
highest coefficients of correlation with muscle strength (0.76
with hand grip and 0.93 with megascore), 6MWD (0.52),
timed tests (0.49 and 0.78), and pulmonary functions (0.68
and 0.86). Interestingly, the correlation between AFFMI and
6MWD was only moderate indicating that the contribution
of muscularity explains only 50% of the performance in the
6MWD. In healthy subjects, it has been shown that age,
height, sex, and weight were independent contributors to the
6MWD, thus, explaining up to 66% of the variability [54–
56]. Finally, AFFMI was also the best single explicator of the
measures of muscle strength and physical function.
6. Conclusions
Collagen typeVI relatedmyopathies, likemostmuscular dys-
trophies, show a wide range of clinical severity that is usually
evaluated with the assessment of muscle strength and physi-
cal function.The best assessment in clinical trials should be as
comprehensive and multidimensional as possible in order to
fully explore the interconnected compromise of muscle mass,
muscle strength, and function. The evaluation of body com-
position, in particular of muscle mass with DXA, explaining
most of the variability of themeasures of muscle strength and
physical function, should be included in clinical trials.
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